CC
Chemours Co Materials Chemicals & Allied Products Russell 3000
$13.53Close
$2.0BMarket cap
$10.33 – $27.6852-week range
Nov 2, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 15 · weaker than 85% of stocks over 12 months
- Far from its high 51% below its 52-week high
- Results soon Nov 2, 2026, in 1 day
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
51%
1wk
up 5.6%
price change
1mo
down 0.3%
price change
12-month return
up 5%
market up 11% ·
its own down 10%
F-score
4 / 9
Weak
Altman Z
1.40
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.1×
price / book
Earnings yield
down 0.1%
EBIT / enterprise value
Cheaper than
29%
of the market · expensive
Revenue growth
0%
year on year
EPS growth
—
latest quarter
Sales growth
down 1%
latest quarter · -2 pts
ROE
down 94%
return on equity
Free cash margin
up 1%
$51.0M FCF
D/E
16.40
long-term debt / equity
Net debt / EBITDA
10.3×
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- gross margin narrowed
- generating cash from operations
- profits backed by cash
- short-term liquidity improved
- assets working harder
Repair signals
- FCF turned positive ($-993M → $51M)
- Revenue reaccelerating (-5% then +0%)
Trade setup
ATR%
3.7%
$0.50 a day · 2×ATR $12.54
RS
15 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
1.1×
vs 50-day average
Up/down volume
0.83
50 sessions
Implied move
—
no option chain · report Nov 2, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Heavily indebted Net debt is 10.3 times EBITDA — roughly 10 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Gross margin narrowing Gross margin fell from 19.8% to 15.5%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Aug 5, 2026-19% in one session3.9× volumeon results-7% since
Financials
- Gross 16%
- Net -7%
- Free cash 1%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $5.0B | $6.3B | $6.8B | $6.1B | $5.8B | $5.8B |
| Gross margin | 21% | 22% | 24% | 21% | 20% | 16% |
| Net income | $219.0M | $608.0M | $578.0M | -$253.0M | $69.0M | -$386.0M |
| Net margin | 4% | 10% | 8% | -4% | 1% | -7% |
| Earnings per share | $1.32 | $3.60 | $3.65 | -$1.70 | $0.46 | -$2.57 |
| Free cash flow | $540.0M | $537.0M | $448.0M | $186.0M | -$993.0M | $51.0M |
| Free cash margin | 11% | 8% | 7% | 3% | -17% | 1% |
| Cash | $1.1B | $1.5B | $1.1B | $1.2B | $713.0M | $670.0M |
| Long-term debt | $4.0B | $3.7B | $3.6B | $4.0B | $4.1B | $4.1B |
| Shareholders' equity | $813.0M | $1.1B | $1.1B | $721.0M | $571.0M | $250.0M |
| Shares outstanding | 164.92m | 161.05m | 148.50m | 148.59m | 149.43m | 149.89m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 18, 2025 | Annual ↗ | Dec 31, 2024 | 49d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| Apr 30, 2024 | Quarterly ↗ | Mar 31, 2024 | 30d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Oct 27, 2023 | Quarterly ↗ | Sep 30, 2023 | 27d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 10, 2026 | Material agreement · Regulation FD ↗ |
| Sep 9, 2026 | Regulation FD ↗ |
| Aug 4, 2026 | Results ↗ |
| Jun 24, 2026 | Material agreement · Regulation FD ↗ |
| May 5, 2026 | Results ↗ |
| Apr 30, 2026 | Director or officer change · Shareholder vote ↗ |
| Mar 12, 2026 | Material agreement · New obligation · Other events ↗ |
| Feb 26, 2026 | Other events ↗ |
| Feb 19, 2026 | Results ↗ |
| Jan 16, 2026 | Material agreement · Regulation FD ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 31, 2025 | Director or officer change ↗ |